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A B S T R A C T
Contrast media used in radiology are iodine based for computed tomography (CT) 
examinations and gadolinium based for magnetic resonance imaging (MRI) ex-
aminations. Initially, gadolinium based contrast media were thought to be safe and 
non-nephrotoxic. Later on, several studies revealed that they can also be nephrotoxic 
at increased doses. Additionally, another complication from their use is systematic 
nephrogenic fibrosis. Gadolinium based contrast media can be safe in healthy and 
renal insufficiency patients if used at specific doses. These complications are herein 
briefly reviewed and guidelines and techniques for their avoidance are discussed.
I n T R o d u C T I o n
The development of radiologic contrast media originated with the use of iodinated 
contrast media in radiography in 1918. A number of ionic high osmolar contrast media 
was synthesized through the 1950s and 1960s. Later, non-ionic low-osmolar contrast 
media were synthesized to minimize the incidence of immediate type hypersensitivity 
reactions to high osmolar contrast media. The incidence of these reactions was further 
lowered by iso-osmolar contrast media.1 The use of iodinated contrast media has been 
increased due to the increased use of radiologic diagnostic modalities and interventional 
angiographic procedures. However, the occurrence of acute renal failure, known as 
contrast media induced nephropathy, is still a major complication. According to the 
guidelines of the Contrast Media Safety Committee of the European Society of Uro-
genital Radiology, contrast media nephrotoxicity is defined as an increase in serum 
creatinine level of 0.5 mg/dl (44 μmol/l) or more or 25% or greater above the baseline 
value occurring within 3 days after intravascular contrast administration without an 
alternative cause.2 
Contrast induced nephropathy has become the third leading cause of acute renal 
failure necessitating hospitalization.3 The overall incidence has been reported between 
1-2%3,4 in the general population and 11% in hospitalized patients.5 However, in patients 
with underlying hypertension, cardiovascular disease, diabetes mellitus or pre-existing 
renal insufficiency, the incidence is higher and may be as high as 20-50%.3,4,6 Other 
risk factors include an increased volume of contrast media use, repeated use within 72 
hours, dehydration, advanced age (over 70 years), intake of concomitant nephrotoxic 
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drugs, multiple myeloma and liver disease.1 Another serious 
adverse reaction of contrast media is nephrogenic systemic 
fibrosis (NSF), which is a fibroproliferative disease confined 
to patients with advanced chronic kidney disease and patients 
with acute renal injury and substantial renal insufficiency. 
Other risk factors that may be associated include edema, 
systemic inflammation and recent surgery. 
In 1988 the Food and Drug Administration of the USA 
approved gadolinium as a contrast agent to provide a clearer 
picture of organs and tissues in patients undergoing magnetic 
resonance imaging (MRI) and magnetic resonance angiog-
raphy (MRA). Gadolinium-based contrast agents have been 
successfully employed to enhance MRI images by affecting 
T1 and T2 relaxation times, providing a stronger MRI signal 
and a brighter image. In order to reduce toxicity, only gado-
linium chelated agents are used. Although initially thought 
to be non-nephrotoxic, conferring a significant advantage 
over the iodinated contrast agents used in X-ray procedures, 
gadolinium based agents have been shown to be nephrotoxic, 
particularly when used in higher dosages and especially in 
patients with chronic renal insufficiency. Furthermore, an as-
sociation between gadolinium based contrast media exposure 
and NSF has also been observed and several risk factors have 
been identified. 
C h A R A C T e R I S T I C S  
o f  G A d o l I n I u m  C h e l A T e S
Gadoliniun (Gd) is a member of lanthanide series of tran-
sition metals. Its biochemical and physiochemical properties 
make it extremely useful as a contrast agent in MRI in order to 
enhance various body organs and tissues. There are many cases 
in which the use of gadolinium is essential such as in brain and 
spinal cord masses, demyelinating diseases, bone tumors and 
infection or rheumatologic diseases and study of abdominal 
or pelvic masses, etc. However, the free ionic form (Gd3+) 
is highly toxic and has been shown to precipitate in tissues 
and obstruct calcium ion passage through muscle and nerve 
cells.1 To prevent the toxic effects it needs to be sequestered by 
nontoxic substances, a chelate such as macrocyclic molecules 
and linear molecules.7 These chelated agents demonstrate a 
500-fold increase in renal excretion when compared with ex-
cretion of free gadolinium.8,9 In general, macrocyclic chelates 
such as gadoterate meglumine or gadoteridol are more stable 
than linear molecules. Non ionic preparations are less stable 
in comparison to ionic preparations (Table 1).10
P h A R m A C o K I n e T I C S  
o f  G A d o l I n I u m  C h e l A T e 
Gadolinium chelates reach rapid equilibrium between 
plasma and interstitial compartments. They do not undergo 
biologic transformation and are eliminated unchanged, almost 
exclusively by glomerular filtration, without any tubular secre-
tion, with mean terminal half-life of 2 hours.1 In patients with 
normal renal function, about 98% of gadolinium chelate is 
excreted within 24 hours in the urine with less than 3% being 
eliminated in the feces.11 In patients with moderate (creati-
nine clearance 30-60 ml/min) or severe renal insufficiency 
(clearance 15-30 ml/min), gadolinium chelate elimination is 
markedly prolonged.1
P R o B A B l e  m e C h A n I S m  
o f  n e P h R o T o x I C I T y  
o f  C o n T R A S T  m e d I A
The pathogenesis of contrast induced nephropathy by 
iodinated contrast media is thought to be due to hypoxic or 
ischemic injury to tubular cells and due to direct toxicity by gen-
eration of reactive oxygen species. Similar to iodinated contrast 
media, gadolinium chelates may result in nephrotoxicity via 
a direct cytotoxic effect on renal tubular cells. Accumulation 
of free Gd3+ has also been suggested as a causative factor of 
contrast induced nephropathy. In patients with normal renal 
function, the excretion of gadolinium complex is rapid and the 
concentration of the free Gd 3+ is very low. On the contrary, 
in patients with reduced renal function there is an increase 
in the elimination half-life of gadolinium chelates, which re-
sults in accumulation of toxic free Gd3+.12 Additionally, free 
Gd3+ can be released in the presence of high concentration 
of competing cations such as copper and zinc, called trans-
metallation, when gadolinium complexes remain in the body 
for a prolonged time13 as in patients with renal insufficiency. 
TABle 1. Gadolinium Chelates Available for Clinical Use
Chemical Compound Type
Approved Iv 
dose  
(mmol/kg)
Gadopentetate dimegumine Ionic linear 0.1-0.3
Gadoteridol Nonionic cyclic 0.1-0.2
Gadoterate Ionic cyclic 0.1-0.2
Gadodiamide Nonionic linear 0.1-0.3
Gadobenate dimeglumine Ionic linear 0.05-0.1
Gadoversetamide Non ionic linear 0.1
Gadobutrol Non ionic cyclic 0.1-0.3
Gadofosveset trisodium Linear ionic 0.01-0.05
IV = intravenous
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R e n A l  S A f e T y  o f  G A d o l I n I u m  B A S e d 
C o n T R A S T  m e d I A  I n  P A T I e n T S  w I T h 
n o R m A l  R e n A l  f u n C T I o n
There are plenty of studies dealing with renal safety in 
patients with normal renal function.14-17 In a retrospective 
study in which the effect of gadolinium chelates was examined 
in healthy individuals, it was observed that no one developed 
contrast induced nephropathy. The authors concluded that 
gadolinium-based agents are safe and well tolerated.18 In 
another retrospective study, serum creatinine levels were 
compared before and after both gadolinium and iodinated 
examinations were performed on separate days within a 
6-month period. Creatinine levels did not increase in patients 
with normal renal function after gadolinium chelate injection, 
in contrast to patients who received iodinated contrast media 
in whom the incidence of contrast induced nephropathy was 
2.6%.19 In another study, no significant difference in serum 
creatinine was observed in patients receiving a mean dose of 
gadolinium chelate of 0.14 mmol/kg in patients with normal 
renal function.20 The reports of gadolinium chelates as contrast 
media in healthy individuals have been uniformly favorable 
in terms of their tolerance and effect on renal function with 
no reported cases of contrast agent induced nephropathy. 
Gadolinium chelates in healthy individuals are safe if used 
intravenously in doses of 0.1 mmol/kg.1
R e n A l  T o x I C I T y  o f  G A d o l I n I u m  I n 
P A T I e n T S  w I T h  R e n A l  I n S u f f I C I e n C y
Over the previous several years, gadolinium based con-
trast media had been considered safe and non-nephrotoxic as 
compared with iodinated ones. However, recent reports have 
questioned this assertion. In one study,21 the authors compared 
patients with a creatinine clearance rate <60 ml/min/1.73 m2 
who received prophylactic intravenous hydration and oral N-
acetylcysteine and gadodiamide-iodine mixture or an iodinated 
contrast media alone during cardiac catheterization. Although 
less iodinated contrast media was used in the gadodiamide 
group, there was no difference in the incidence of contrast 
induced nephropathy between the two groups. The authors 
concluded that the incidence of contrast induced nephropathy 
was not decreased in high risk patients receiving a gadolinium-
chelate-iodinated mixture rather than iodinated alone. 
Case reports of acute renal failure after administering a 
gadolinium dose of 0.1-0.44 mmol/kg in patients with renal 
insufficiency have appeared in the literature.22-24 All patients 
had diabetes mellitus (DM) type 2 and/or hypertension. Renal 
biopsies suggested acute tubular necrosis. In another study, 
deterioration of renal function occurred after intra-arterial 
administration of a dose >0.2 mmol/kg in patients with renal 
insufficiency (creatinine clearance <60 ml/min/1.73 m2), which 
is frequently associated with DM or hypertension.1 Moreover, 
another study concluded that underlying renal insufficiency, 
DM and cardiovascular disease must be identified before the 
patient receives gadolinium chelate and doses should not be 
greater than 0.4 mmol/kg.25 In another study,26 no change in 
renal function occurred after injection of 0.1 mmol/kg of ga-
dodiamide in patients with severely impaired renal function 
(glomerular filtration rate-GFR of 2-10 ml/min/1.73m2) and 
in patients undergoing hemodialysis or peritoneal dialysis. 
Gadodiamide injection was followed by 500 ml of saline ad-
ministered intravenously during the first 3 hours. In this study, 
none of the patients who had diabetes or received drugs was 
suspected of having a nephrotoxic effect. 
In a retrospective study,27 it was suggested that gadolin-
ium-based contrast media can induce acute kidney injury in 
patients with renal impairment with the usual dose for MRI 
examinations. After all other causes of acute kidney disease, 
such as severe heart failure and shock, were excluded, the 
authors observed a decrease in GFR >10% of baseline value 
within 3 days after administration of contrast media. However, 
sepsis was an independent risk factor. They concluded that in 
patients with renal impairment, administration of gadolinium 
based contrast media under sepsis milieu can induce acute 
kidney injury.
It is difficult to reach a firm conclusion regarding nephro-
toxicity of gadolinium based contrast media. Ledneva et al,1 
in a review study, suggest that gadolinium chelates appear 
safe and non nephrotoxic as intravenous contrast media for 
MRI or MRA in patients with normal renal function and 
in patients with preexisting renal insufficiency when used 
in doses similar to those recommended for MRI. However, 
deterioration in renal function may occur in the majority of 
cases after intraarterial administration of gadolinium based 
contrast media at doses higher than 0.2 mmol/kg for diagnostic 
or interventional angiographic procedures in patients with 
renal insufficiency (creatinine clearance <60 ml/min/1.73m2), 
which is frequently associated with DM and/or hypertension. 
Therefore, although high doses of gadolinium based contrast 
media (>0.2-0.3 mmol/kg) are administered safely in patients 
with renal insufficiency, the clinical use of doses >0.2 mmol/
kg should be avoided in these patients, especially when ad-
ministered intraarterially.
n e P h R o G e n I C  S y S T e m I C  f I B R o S I S 
( n S f )
Another complication after use of gadolinium contrast me-
dium in patients with renal impairment, particularly in patients 
with GFR <30 ml/min/1.73m2, is NSF. It is a fibroproliferative 
disease confined to patients with advanced chronic kidney dis-
ease and patients with acute renal injury and substantial renal 
insufficiency. The first case of this pathology was observed in 
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1997 and the disease was initially reported in 2000 in a case 
series of 14 patients undergoing hemodialysis.28 Histologically, 
it is characterized by thickened collagen bundles, mucin depo-
sition and the presence of CD34+/CD45RO+/type I procol-
lagen+ and or CD68+/factor XIIIa+ cells in affected areas.29
PA T h o G e n e S I S
Transmetallation with dissociation of free gadolinium from 
its chelate has been suggested as a cause. Free gadolinium then 
binds with other anions such as phosphate, bicarbonate and 
deposits in tissues of patients with renal impairment. It then 
induces fibrosis through macrophage-induced phagocytosis 
and consequent release of cytokines and growth factors.30 
It has been suggested that spindle cells involved in NSF are 
circulating fibrocytes (CD 34/procollagen I positive cells) that 
are normally present in the blood and are involved in wound 
repair. These circulating fibrocytes would be aberrantly re-
cruited to dermis in the absence of overt tissue injury.31,32 Other 
investigators observed the expression of transforming growth 
factor beta 1, which is a potent stimulus for the production of 
collagen I by some cell types and mediates interstitial fibrosis.33 
In an in vitro study,30 whereby the effect of contrast agents 
on hyaluronan and collagen synthesis was observed, the follow-
ing conclusions were reached. The linear gadolinium contrast 
agents (gadodiamide, gadoversetamide, gadopentetate dime-
glumine and gadobenate dimeglumine) produce a maximum 
stimulation of fibroblast proliferation at a concentration of 
0.1 mmol/L, with cell numbers increasing up to 2.3-fold after 
a 4-day exposure. The macrocyclic contrast agents (gadoteric 
acid and gadoteridol) produced a maximum stimulation of 
fibroblast proliferation at a concentration of 5 mmol/L and 
increase cell numbers up to 1.6-fold after 4 days of exposure. 
Finally, they suggested that not only free gadolinium but 
chelated gadolinium may also be bioactive in stimulating 
fibroblast proliferation meaning that all gadolinium-based 
contrast agents are associated with this risk when injected at 
high doses.30 
Among published cases of NSF, the interval between 
gadolinium administration and NSF onset has varied widely, 
from <10 days to 68 months; however, most patients developed 
NSF within 2 months after exposure.34,35 Several investigators 
have also suggested that a higher cumulative dose increases 
the likelihood of developing NSF.34 Another study suggested 
that the volume and dose infused closely to the onset of 
symptoms correlated better with the incidence of NSF than 
cumulative volumes and doses over longer time intervals.29 A 
number of other factors have been postulated to explain why 
some patients with severe chronic kidney disease who are ex-
posed to gadolinium contrast media develop NSF and others 
do not. These include metabolic acidosis or medications that 
predispose patients to acidosis,36,37 increased iron, calcium and 
or phosphate levels,37,38 high dose erythropoietin therapy, im-
munosuppresion,39 vasculopathy,40 an acute pro-inflammatory 
event41 and infection.42 None of these potential risk factors 
have been demonstrated to be present in all affected patients. 
Therefore, none of these can be considered as a true co-factor 
with high degree of confidence.43
Nephrogenic systemic fibrosis has also developed in 
patients with acute kidney disease,44 even if renal function 
subsequently returned to normal following gadolinium based 
contrast media.45 In one series, up to 20% of NSF cases were 
diagnosed in patients who had been in some degree of tran-
sient acute renal failure (often, but not always superimposed 
upon chronic renal disease) at the time of contrast media 
administration.46 
C l I n I C A l  P R e S e n T A T I o n
Nephrogenic systemic fibrosis typically manifests with 
extensive thickening and hardening of the skin with hyperpig-
mentation, plaques, papules and nodules and a peau d’orange 
appearance. It begins at distal extremities and may involve 
the trunk. The lesions are frequently erythematous, pruritic 
and /or painful. Restriction of joint movements results in 
progressive disability.29 However, systemic involvement with 
fibrosis of other organs such as lung parenchyma, the pleura, 
pericardium, myocardium, diaphragm, kidneys, testes and 
striated muscle has been reported. Thus, this entity has been 
named “nephrogenic systemic fibrosis”.47 Other clinical find-
ings are dyspnea, paresthesias and ocular manifestations, such 
as diplopia, uveitis and scleritis. The presence of cutaneous 
changes is associated with a 3-5-fold increased risk of dying.48 
Death is usually due to complications related to limited motility 
and respiratory failure.
G u I d e l I n e S  T o  P R e v e n T  n S f
According to a study49 it is suggested that in order to 
minimize side effects of contrast media, the patients should 
be identified as high risk and noncontrast based imaging tech-
niques should be used as long as they are suitable and safe. 
If the risk benefit ratio of the imaging information favors a 
contrast study, then use of contrast media of lowest complica-
tion risks should be used after obtaining informed consent, at 
a dose limited to 0.1 mmol/kg.50
In a recent retrospective study in a large academic center, 
the incidence of NSF was determined after the adoption of 
administration guidelines for the use of restrictive gadolinium 
–based contrast agent. These require (a) a recent serum 
creatinine level measurement in any patient who is aged 60 
years or older and/or at risk for renal disease, (b) limiting the 
maximal weight-based dose administered to any patient with 
an estimated GFR (eGFR) <60 ml/min/m2 to 20 ml, and (c) 
prohibiting the administration of gadolinium based contrast 
media in patients who have an eGFR<30 ml/min/m2 and/or 
are undergoing chronic dialysis treatment (except in emer-
gency situations). They concluded that after these restrictive 
guidelines were instituted, no new cases of NSF were identi-
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fied.51 Similar results are reported in another study in which 
the authors observed a decrease of the incidence of NSF if 
gadolinium based contrast media were not administered to 
patients with creatinine clearance <30 ml/min/1.73m2.52 
Specific recommendations for patients with end-stage renal 
disease on chronic dialysis have been proposed. In detail, if 
a contrast enhanced cross-sectional imaging study is required 
in an anuric patient with no residual renal function, it would 
be reasonable to consider administering iodinated contrast 
media and performing CT rather MRI. If a contrast-enhanced 
MRI must be performed, gadodiamide, gadopentetate dimeg-
lumine and gadoversetamide should be avoided. Also, use of 
the lowest possible dose needed to obtain a diagnostic study 
is suggested and MRI examination should be performed as 
close to hemodialysis as possible. Many experts recommend 
that consideration should be given to the performance of 
several dialysis sessions following MRI examination, with 
use of prolonged dialysis times and increased flow rates and 
volumes. Peritoneal dialysis provides much less potential NSF 
risk reduction and should not be considered protective.43
Additionally, for patients with chronic kidney disease 
(eGFR<30 ml/min/1.73m2) not on chronic dialysis or patients 
with eGFR of 30-44 ml/min/1.73m2, it is recommended to 
avoid any contrast media either iodinated or gadolinium. If 
MRI contrast media administration is essential, use of lowest 
possible dose needed is recommended. Again, gadodiamide, 
gadopentetate dimeglumine and gadoversetamide should be 
avoided. It is suggested not to re-administer gadolinium based 
contrast media for several days to a week. For patients with 
eGFR of 45-59 ml/min/1.73m2, risk of development of NSF 
is extremely small and it is recommended to use the lowest 
dose to obtain a diagnostic study. A decision to administer 
gadodiamide, gadopentetate dimeglumine or gadoversetamide 
should be made only following appropriate risk-benefit assess-
ment. In patients with chronic kidney disease and eGFR of 
60-110ml/min/1.73m2, there is no evidence of increased risk 
of developing NSF. All gadolinium based contrast media can 
be administered safely in these situations.43
Patients with acute renal failure are at risk of developing 
NSF. Gadolinium based contrast media should only be admin-
istered if it is absolutely necessary. If such an examination is 
required, then use of lowest possible dose needed is recom-
mended and gadodiamide, gadopentetate dimeglumine or 
gadoversetamide should be avoided.43 
A l T e R n A T I v e  T e C h n I q u e S
The concern about a possible link between gadolinium 
based contrast agents and NSF has stimulated further de-
velopment of alternative techniques that do not require ex-
ogenous contrast media. Several such techniques have been 
developed.53 An example of an alternative non contrast study 
to contrast induced MR angiography is reported in a recent 
study.54 The use of rapid (quiescent-interval single shot) un-
enhanced MR angiography for the study of peripheral arte-
rial disease in symptomatic diabetic population is suggested. 
Thus, according to the results of this study, quiescent-interval 
single-shot unenhanced MR angiography with a sensitivity of 
92.1% and a specificity of 96.8% was an accurate non contrast 
alternative to contrast enhanced MR angiography for showing 
clinically significant arterial disease in patients with diabetes 
and symptomatic peripheral disease. 
o T h e R  A C u T e  A d v e R S e  R e A C T I o n S  o f 
G A d o l I n I u m  B A S e d  C o n T R A S T  m e d I A 
In addition to the side-effects already described, after 
administration of gadolinium based contrast media, other 
acute adverse reactions have also been observed. They are 
encountered with a lower frequency than that observed after 
administration of iodinated contrast media. The frequency of 
all acute adverse events after an injection of 0.1 or 0.2 mmol/
kg of gadolinium chelate ranges from 0.07% to 2.4%. The 
vast majority of these reactions are mild, including coldness at 
the injection site, nausea with or without vomiting, headache, 
warmth or pain at the injection site, paresthesias, dizziness 
and itching. Reactions resembling an allergic response are 
very unusual and vary in frequency from 0.004% to 0.7%. A 
rash, hives or utricaria are the most frequent of these reactions 
and very rarely may bronchospasm occur. Severe life threaten-
ing anaphylactoid or non allergic anaphylactic reactions are 
extremely rare (0.001%-0.01%).43 Fatal reactions may occur 
but are extremely rare. Overall, ionic linear gadolinium- based 
contrast agents have a significantly higher rate of immediate 
adverse events compared to nonionic linear gadolinium based 
contrast agents.54 
C o n C l u S I o n
Use of gadolinium chelates in healthy individuals is safe 
and well tolerated by patients. Αcute adverse reactions after 
administration of gadolinium based contrast media are rare. 
They are mild in severity. Death is extremely rare. However, 
contrast induced nephropathy is a complication after injection 
of gadolinium based contrast media in patients with renal 
insufficiency who also have other risk factors especially if a 
high dose is used. In patients with normal renal function these 
agents are safe and non nephrotoxic with a suggested dose of 
0.1 mmol/kg. Another complication after the use of gadolinium 
contrast medium in patients with renal impairment, particu-
larly in patients with GFR <30 ml/min/1.73m2, is NSF, which 
is a fibroproliferative disease. Several guidelines have been 
developed in order to avoid contrast induced nephropathy 
and NSF and should be closely followed.
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